Vertex Pharmaceuticals Inc Fourth Quarter Earnings Sneak Peek

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will unveil its latest earnings tomorrow, Tuesday, January 29, 2013. Vertex Pharmaceuticals is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Vertex Pharmaceuticals Incorporated Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for a loss of 13 cents per share, up from net income of 75 cents in the year-earlier quarter. During the past three months, the average estimate has moved down from 12 cents. Between one and three months ago, the average estimate moved down. It also has dropped from a loss of 10 cents during the last month.

Start 2013 better than ever by saving time and making money with your Limited Time Offer for our highly-acclaimed Stock Picker Newsletter. Click here for our fresh Feature Stock Pick now!

A Look Back: In the third quarter, the company swung to a loss of $57.5 million (27 cents a share) from a profit of $221.1 million ($1.02) a year earlier, missing analyst expectations. Revenue fell 49% to $336 million from $659.2 million.

Here’s how Vertex Pharmaceuticals Inc traded following its last earnings report 3 months ago and leading up to its upcoming earnings report this week:

vrtx

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Premium Newsletters

Stock Investor Cheat Sheet

Stock Investor Cheat Sheet®

The ultimate Cheat Sheet for finding winning stock picks.
Learn More

Gold & Silver Newsletter

Gold & Silver

Don't miss one of the biggest bull markets in history! Covers Gold, Silver, Gold & Silver stocks, and miners.
Learn More

Commodities Premium Newsletter

Commodities Premium

There's always a bull market in some sector! Find the best opportunities in commodities.
Learn more

ETF Investing

ETF Investing

At last, a trading system that buys the right ETFs at the right time, time after time!
Learn more

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business